Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 100.45B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 15.82 |
| Forward PE | 10.05 |
| Dividend | 3.92 (4.87%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 1,680,655 |
| Average Volume | 1,871,021 |
| Open | 80.50 |
| Previous Close | 80.50 |
| Day's Range | 80.50 - 82.63 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.40 |
| RSI | 48.42 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi sees softness in U.S. vaccine demand in near term
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year due to misinformation and heightened scrutiny under the current administrat...
Sanofi: Information concerning the total number of voting rights and shares - December 2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sandoz Secures European Commission Approval For Ondibta, A Biosimilar To Lantus, For Diabetes
(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ac...
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
Sanofi SA at JPMorgan Healthcare Conference Transcript
Sanofi SA at JPMorgan Healthcare Conference Transcript
Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sanofi (SNY) CEO Highlights Key Insights at JPMorgan Healthcare Conference
Sanofi (SNY) CEO Highlights Key Insights at JPMorgan Healthcare Conference
Dynavax gains on disclosure another bidder interested after deal announced
Dynavax (DVAX) stock rises after a mystery bidder shows interest despite Sanofi’s $2.2B, $15.50/share deal.
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025
Sanofi Wins EU Approval For Teizeild In Stage 2 Type 1 Diabetes
(RTTNews) - Sanofi (SNY) announced that the European Commission has approved Teizeild for adult and pediatric patients aged eight years and older with stage 2 type 1 diabetes.
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa...
Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D pa...
BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence
BrightInsight Patient App improved treatment adherence and decreased discontinuation rate for for one of Sanofi and Regeneron's key biologic therapies.
Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities
CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), announced toda...
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi's (SNY) Tzield Under Priority Review for Type 1 Diabetes
Sanofi's (SNY) Tzield Under Priority Review for Type 1 Diabetes
Sanofi’s Tzield accepted for FDA priority review in younger type 1 diabetes patients
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
FDA Accepts Sanofi's Tzield SBLA Priority Review To Expand Use In Children 1+ For Type 1 Diabetes
(RTTNews) - Sanofi (SNY, SAN.PA) announced that the U.S. Food and Drug Administration has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv)...
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1...
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1...
Witnessing An Insider Decision, George L Sing Exercises Options Valued At $2.32M At Regeneron Pharmaceuticals
In a new SEC filing on December 31, it was revealed that Sing, Board Member at Regeneron Pharmaceuticals (NASDAQ: REGN), executed a significant exercise of company stock options. What Happened: A For...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
NEW YORK and NEW ORLEANS, Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan
A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements bef...